ArticleFrontiers in veterinary science2026
Chelerythrine potentiates meropenem activity against NDM-producing carbapenem-resistant Enterobacteriaceae.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: NDM-driven carbapenem-resistant Enterobacteriaceae (CRE) are spreading globally, posing a serious One Health threat that extends to veterinary medicine through transmission among food-producing animals, companion animals, and the farm-to-food continuum. Antibiotic adjuvants that restore or potentiate the activity of existing antibiotics represent a promising strategy to address this challenge. Methods: In this study, we evaluated the ability of the natural benzophenanthridine alkaloid chelerythrine to potentiate meropenem activity against NDM-producing Enterobacteriaceae. Antibacterial synergy was assessed using checkerboard assays, resistance development assays, Galleria mellonella infection models, and a murine thigh infection model. The underlying mechanism was investigated through NDM enzymatic activity assays, Zn Results: Chelerythrine strongly potentiated meropenem activity against blaNDM-1-, blaNDM-5-, and blaNDM-9-positive Enterobacteriaceae, with FICI values ranging from 0.18 to 0.31. Chelerythrine markedly delayed the emergence of meropenem resistance. Combination therapy increased survival to 75% in infected Galleria mellonella larvae and significantly reduced bacterial burden in the murine thigh infection model. Mechanistically, chelerythrine inhibited NDM enzymatic activity by occupying the catalytic pocket and interacting with residues surrounding the dinuclear Zn Discussion: These findings demonstrate that chelerythrine restores meropenem efficacy against NDM-producing Enterobacteriaceae through a dual mechanism involving suppression of metallo-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.